Skye Bioscience Inc. Faces Multiple Class‑Action Litigation Filings
Skye Bioscience Inc. (NASDAQ: SKYE) has been the subject of a wave of securities‑law litigation filings and investor‑rights notices in the final days of 2025. The filings involve several prominent law firms and target shareholders who purchased shares between November 4, 2024 and October 3, 2025.
Key Litigation Developments
| Date | Source | Filing or Notice | Law Firm | Relevant Details |
|---|---|---|---|---|
| 2025‑12‑23 | feeds.feedburner.com | Class‑action lawsuit filed against Skye Bioscience | Gross Law Firm | Notice to shareholders that purchased shares during the period; legal options available. |
| 2025‑12‑23 | feeds.feedburner.com | Shareholder action notice issued | Faruqi & Faruqi, LLP | Partner James (Josh) Wilson encourages investors who suffered losses to contact him directly (phone numbers 877‑247‑4292 or 212‑983‑9330, Ext. 1310). |
| 2025‑12‑23 | feeds.feedburner.com | Portnoy Law Firm announces class action on behalf of Skye shareholders | Portnoy Law Firm | Notice of impending litigation. |
| 2025‑12‑24 | www.pr‑inside.com | Pomerantz LLP moves forward with class‑action litigation | Pomerantz LLP | Filing in the U.S. District Court for the Southern District of California. |
| 2025‑12‑23 | feeds.feedburner.com | Levi & Korsinsky reminder of lead plaintiff deadline (January 16, 2026) | Levi & Korsinsky | Deadline for lead plaintiff filing in the class action. |
| 2025‑12‑22 | www.globenewswire.com | Rosen Law Firm urges investors to secure counsel before January 16, 2026 deadline | Rosen Law Firm | Notice specifically to purchasers of Skye shares during the stated period. |
Investor‑Rights Notices
- Faruqi & Faruqi, LLP: Partner Josh Wilson has publicly invited shareholders who incurred losses to discuss their legal rights. The firm’s contact information is provided for direct engagement.
- Rosen Law Firm: A global investor‑rights firm has reminded investors of the importance of obtaining counsel before the January 16, 2026 deadline.
- Gross Law Firm: The firm has issued a notice to shareholders about the class action, indicating that those who bought shares during the specified timeframe should consider their options.
Legal Context
The class actions are filed in the United States District Court for the Southern District of California, with additional filings in other jurisdictions (e.g., filings referenced by the Gross Law Firm and Pomerantz LLP). The lawsuits allege securities‑law violations by Skye Bioscience Inc. and certain officers, and seek compensation for shareholders who purchased shares between November 4, 2024 and October 3, 2025.
Company Overview
Skye Bioscience Inc. is a biotechnology company incorporated in the United States and listed on the Nasdaq exchange. As of December 22, 2025, the company’s market capitalization stood at approximately $26.1 million. The company’s stock closed at $0.85 on December 22, 2025, after reaching a 52‑week high of $5.75 on June 26, 2025, and a 52‑week low of $0.822 on December 21, 2025. The price‑earnings ratio is negative, at -2.58, reflecting the company’s current earnings performance.
Note: This article compiles publicly available information from the specified sources and does not constitute legal advice. Shareholders should consult qualified counsel regarding their rights and potential remedies.
